HANSOH PHARMAC Revenue vs. Price To Earning
| 3KY Stock | EUR 2.14 0.02 0.93% |
For HANSOH PHARMAC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HANSOH PHARMAC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HANSOH PHARMAC HD 00001 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HANSOH PHARMAC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HANSOH PHARMAC HD 00001 over time as well as its relative position and ranking within its peers.
HANSOH |
HANSOH PHARMAC HD Price To Earning vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining HANSOH PHARMAC's current stock value. Our valuation model uses many indicators to compare HANSOH PHARMAC value to that of its competitors to determine the firm's financial worth. HANSOH PHARMAC HD 00001 is rated below average in revenue category among its peers. It is rated third in price to earning category among its peers . The ratio of Revenue to Price To Earning for HANSOH PHARMAC HD 00001 is about 258,238,819 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HANSOH PHARMAC's earnings, one of the primary drivers of an investment's value.HANSOH Revenue vs. Competition
HANSOH PHARMAC HD 00001 is rated below average in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 3.97 Trillion. HANSOH PHARMAC adds roughly 9.97 Billion in revenue claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
HANSOH Price To Earning vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
HANSOH PHARMAC |
| = | 9.97 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
HANSOH PHARMAC |
| = | 38.60 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
HANSOH Price To Earning Comparison
HANSOH PHARMAC is rated second in price to earning category among its peers.
HANSOH PHARMAC Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in HANSOH PHARMAC, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HANSOH PHARMAC will eventually generate negative long term returns. The profitability progress is the general direction of HANSOH PHARMAC's change in net profit over the period of time. It can combine multiple indicators of HANSOH PHARMAC, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people.
HANSOH Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on HANSOH PHARMAC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HANSOH PHARMAC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HANSOH PHARMAC's important profitability drivers and their relationship over time.
Use HANSOH PHARMAC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HANSOH PHARMAC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HANSOH PHARMAC will appreciate offsetting losses from the drop in the long position's value.HANSOH PHARMAC Pair Trading
HANSOH PHARMAC HD 00001 Pair Trading Analysis
The ability to find closely correlated positions to HANSOH PHARMAC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HANSOH PHARMAC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HANSOH PHARMAC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HANSOH PHARMAC HD 00001 to buy it.
The correlation of HANSOH PHARMAC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HANSOH PHARMAC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HANSOH PHARMAC HD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HANSOH PHARMAC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your HANSOH PHARMAC position
In addition to having HANSOH PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Value Funds Thematic Idea Now
Small Value Funds
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in HANSOH Stock
To fully project HANSOH PHARMAC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HANSOH PHARMAC HD at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HANSOH PHARMAC's income statement, its balance sheet, and the statement of cash flows.